Pharmacology of Insulin and Glucagon

Introduction/Overview

The pancreatic hormones insulin and glucagon represent the principal endocrine regulators of fuel metabolism, orchestrating the storage and mobilization of energy substrates to maintain systemic glucose homeostasis. Their opposing yet complementary actions form a critical bi hormonal axis, the dysfunction of which underlies diabetes mellitus, a prevalent and clinically significant metabolic disorder. An in-depth understanding of the pharmacology of these agents is fundamental for the rational management of diabetes and related metabolic conditions. The development of exogenous insulin formulations marked a transformative advancement in medicine, converting type 1 diabetes from a fatal disease to a manageable chronic condition. Concurrently, glucagon serves as an essential therapeutic agent for the emergency treatment of severe hypoglycemia. Mastery of their pharmacodynamics, pharmacokinetics, and clinical applications is therefore indispensable for healthcare practitioners.

Learning Objectives

• Describe the molecular mechanisms of action of insulin and glucagon at cellular and systemic levels.
• Compare and contrast the pharmacokinetic profiles of various insulin formulations, including rapid-acting, short-acting, intermediate-acting, and long-acting analogs.
• Identify the approved therapeutic indications for insulin and glucagon, along with their respective roles in diabetes management and emergency care.
• Analyze the spectrum of adverse effects associated with insulin and glucagon therapy, with particular emphasis on hypoglycemia and its management.
• Evaluate special considerations for the use of these hormones in specific patient populations, such as those with renal impairment, pregnant individuals, and pediatric patients.

Classification

Insulin and glucagon are polypeptide hormones secreted by the islets of Langerhans within the pancreas. Their classification is based on origin, chemical structure, and duration of action for therapeutic formulations.

Chemical and Source Classification

Insulin is a 51-amino acid peptide hormone composed of two polypeptide chains (A and B) linked by two disulfide bonds. It is synthesized and secreted by the beta (β) cells of the pancreatic islets. Historically, therapeutic insulin was derived from bovine or porcine pancreata. Modern therapy predominantly utilizes human insulin produced by recombinant DNA technology or insulin analogs, which are structurally modified forms of human insulin designed to alter pharmacokinetic properties.

Glucagon is a 29-amino acid single-chain polypeptide hormone secreted by the alpha (α) cells of the pancreatic islets. Therapeutic glucagon is also produced via recombinant DNA technology.

Therapeutic Insulin Formulations

Insulin preparations are classified primarily by their onset, peak, and duration of action, which are determined by the formulation.

• Rapid-acting insulin analogs: Insulin lispro, insulin aspart, insulin glulisine. These are characterized by a rapid onset (5-15 minutes) and short duration (3-5 hours) due to modifications that prevent hexamer formation, allowing for faster subcutaneous absorption.
• Short-acting (regular) insulin: Human regular insulin. This has an onset of 30-60 minutes, a peak at 2-3 hours, and a duration of 5-8 hours. It exists in solution as hexamers that must dissociate into monomers for absorption.
• Intermediate-acting insulin: Neutral Protamine Hagedorn (NPH) insulin. This is a suspension of insulin complexed with protamine, resulting in delayed absorption. Onset is 1-2 hours, peak is 4-12 hours, and duration is 12-18 hours.
• Long-acting insulin analogs: Insulin glargine, insulin detemir, insulin degludec. These are designed for a prolonged, relatively peakless profile. Insulin glargine precipitates at subcutaneous pH, forming a depot. Insulin detemir binds to albumin. Insulin degludec forms multihexamers. Their durations range from 16-24 hours (detemir) to beyond 24 hours (glargine U-100, degludec).
• Ultra-long-acting insulin: Insulin glargine U-300 (a more concentrated formulation) and insulin degludec provide durations of action exceeding 24 hours with minimal peak.
• Premixed insulin formulations: Fixed-ratio combinations of rapid- or short-acting insulin with intermediate-acting insulin (e.g., 70/30 NPH/regular, 75/25 lispro protamine/lispro).

Glucagon Formulations

• Injectable glucagon: Lyophilized powder for reconstitution for intramuscular, subcutaneous, or intravenous administration.
• Intranasal glucagon: A dry powder formulation administered into the nasal cavity, approved for severe hypoglycemia.
• Auto-injector and pre-filled syringe devices: Designed for ease of use by caregivers in emergency settings.

Mechanism of Action

Insulin Pharmacodynamics

Insulin acts as the primary anabolic hormone, promoting the storage of carbohydrates, fats, and proteins. Its effects are mediated through binding to the insulin receptor, a transmembrane tyrosine kinase receptor present on target cells, most notably hepatocytes, adipocytes, and myocytes.

Receptor Activation and Signaling Cascade

Insulin binding induces a conformational change in the receptor’s α-subunits, leading to autophosphorylation of tyrosine residues on the intracellular β-subunits. This activates the receptor’s intrinsic tyrosine kinase activity, which phosphorylates intracellular docking proteins, principally insulin receptor substrates (IRS-1 to IRS-4). Phosphorylated IRS proteins serve as docking sites for proteins containing Src homology 2 (SH2) domains, initiating several key signaling pathways:

• The PI3-Kinase/Akt Pathway: This is the primary metabolic pathway. Recruitment and activation of phosphatidylinositol 3-kinase (PI3K) leads to the generation of phosphatidylinositol (3,4,5)-trisphosphate (PIP₃) at the plasma membrane. PIP₃ recruits phosphoinositide-dependent kinase-1 (PDK1) and protein kinase B (Akt). Activated Akt mediates most of insulin’s metabolic actions by phosphorylating downstream targets.
• The MAP Kinase Pathway: Activation of the Ras/Raf/MEK/ERK cascade primarily regulates gene expression, cell growth, and differentiation.

Cellular and Systemic Effects

The activation of these pathways leads to coordinated tissue-specific effects:

Liver: Insulin suppresses hepatic glucose output via dual mechanisms. It inhibits glycogenolysis (breakdown of glycogen) and gluconeogenesis (synthesis of glucose from precursors like lactate and amino acids). Concurrently, it promotes glycogenesis (glycogen synthesis) and lipogenesis (fatty acid synthesis).

Muscle: Insulin stimulates the translocation of glucose transporter type 4 (GLUT4) vesicles from intracellular stores to the plasma membrane, markedly increasing glucose uptake. It also promotes amino acid uptake and protein synthesis while inhibiting protein degradation.

Adipose Tissue: Insulin facilitates GLUT4-mediated glucose uptake. It promotes lipid storage by activating lipoprotein lipase (which hydrolyzes circulating triglycerides for uptake) and by inhibiting hormone-sensitive lipase (which prevents intracellular triglyceride breakdown). It also enhances fatty acid esterification.

Other Tissues: Insulin exerts mitogenic effects and influences electrolyte balance, notably promoting potassium influx into cells.

Glucagon Pharmacodynamics

Glucagon functions as a counter-regulatory hormone, opposing insulin’s actions to mobilize energy stores during fasting or stress. It acts primarily on the liver via binding to a specific G protein-coupled receptor (GPCR).

Receptor Activation and Signaling

The glucagon receptor is coupled primarily to the stimulatory G protein (G_s). Receptor activation leads to the dissociation of the G_s α-subunit, which activates adenylate cyclase. This enzyme catalyzes the conversion of ATP to cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP levels activate protein kinase A (PKA), which phosphorylates key regulatory enzymes.

Cellular and Systemic Effects

Liver: Glucagon’s most critical actions occur in hepatocytes. PKA-mediated phosphorylation activates glycogen phosphorylase (stimulating glycogenolysis) and inhibits glycogen synthase. It also upregulates gluconeogenesis by increasing the transcription of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase. The net result is a rapid increase in hepatic glucose production and release into the circulation.

Adipose Tissue: Glucagon stimulates lipolysis in adipocytes, though this effect is more pronounced in rodents than in humans. In humans, its lipolytic action is considered minor compared to that of catecholamines.

Other Effects: Glucagon has positive inotropic and chronotropic effects on the heart, independent of β-adrenergic receptors. It relaxes smooth muscle in the gastrointestinal tract (spasmolytic effect) and stimulates insulin secretion from pancreatic β-cells, a paradoxical feed-forward mechanism.

Pharmacokinetics

Insulin Pharmacokinetics

The pharmacokinetics of insulin are complex and highly dependent on the formulation, route of administration, injection site, and individual patient factors.

Absorption

The primary route of administration is subcutaneous injection. Absorption from the subcutaneous tissue is the rate-limiting step for all formulations except intravenous regular insulin. Factors influencing absorption include:

• Formulation: Soluble analogs (lispro, aspart) are absorbed fastest. Protamine or zinc complexes (NPH, lente) form depots that delay absorption. Precipitation (glargine) or albumin binding (detemir) further prolongs action.
• Injection Site: Absorption is generally fastest from the abdomen, followed by the arm, buttock, and thigh. Site rotation is recommended to prevent lipohypertrophy, which can impair absorption.
• Blood Flow: Increased local blood flow (e.g., from heat, massage, exercise) accelerates absorption.
• Depth of Injection: Intramuscular injection, which may occur inadvertently, results in faster absorption than subcutaneous administration.

Intravenous administration is used in critical care settings (e.g., diabetic ketoacidosis) and results in immediate bioavailability with a very short half-life (≈5 minutes). Inhaled insulin is also available, offering rapid absorption via the pulmonary alveoli.

Distribution

Endogenous and exogenous insulin distributes into a volume roughly equivalent to the extracellular fluid. It does not cross the blood-brain barrier readily. The distribution phase after subcutaneous injection is incorporated into the overall absorption profile.

Metabolism and Excretion

Insulin is metabolized primarily in the liver (≈60%) and kidneys (≈30-40%) via proteolytic degradation, including insulin-degrading enzyme. Renal clearance becomes increasingly important in renal impairment, potentially prolonging insulin’s half-life. Only small, insignificant amounts appear unchanged in the urine.

Pharmacokinetic Parameters of Key Formulations

The following table summarizes approximate pharmacokinetic parameters after subcutaneous administration:

Rapid-acting analogs (lispro, aspart, glulisine): Onset: 5-15 min; Peak: 30-90 min; Duration: 3-5 hours.

Short-acting (Regular): Onset: 30-60 min; Peak: 2-3 hours; Duration: 5-8 hours.

Intermediate-acting (NPH): Onset: 1-2 hours; Peak: 4-12 hours; Duration: 12-18 hours.

Long-acting analogs:

Glargine U-100: Onset: 2-4 hours; Peak: relatively peakless; Duration: 20-24 hours.

Detemir: Onset: 1-2 hours; Peak: 6-8 hours (minimal); Duration: 16-24 hours.

Degludec: Onset: 1-2 hours; Peak: peakless; Duration: >42 hours.

Glucagon Pharmacokinetics

Absorption

Glucagon is a peptide and must be administered parenterally or intranasally. After intramuscular or subcutaneous injection, absorption is generally rapid, with a time to peak plasma concentration (t_max) of approximately 10-20 minutes. Intranasal powder is absorbed through the nasal mucosa, with a t_max of around 15-20 minutes. Intravenous administration results in an immediate effect.

Distribution

Glucagon distributes widely throughout the extracellular space. Its precise volume of distribution is approximately 0.25 L/kg.

Metabolism and Excretion

Glucagon is extensively metabolized in the liver, kidneys, and plasma. Its metabolic clearance rate is high. The plasma elimination half-life (t_1/2) is short, approximately 3-10 minutes, but its hyperglycemic effect persists for 60-90 minutes due to the sustained metabolic response in the liver.

Therapeutic Uses/Clinical Applications

Therapeutic Uses of Insulin

• Type 1 Diabetes Mellitus: Absolute insulin deficiency necessitates lifelong exogenous insulin replacement therapy. Regimens typically involve basal-bolus therapy (a long-acting basal insulin plus rapid-acting bolus insulin with meals) or continuous subcutaneous insulin infusion (insulin pump).
• Type 2 Diabetes Mellitus: Insulin is initiated when glycemic control is not achieved with non-insulin antihyperglycemic agents, often due to progressive β-cell failure. It may be used as add-on therapy or as a standalone regimen. Common starting strategies include basal insulin alone or premixed insulin.
• Gestational Diabetes Mellitus: Insulin is the preferred pharmacologic agent if medical nutrition therapy fails to achieve glycemic targets, as it does not cross the placenta.
• Hyperglycemic Emergencies: Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are treated with continuous intravenous infusion of regular insulin.
• Perioperative and Critical Care Management: Insulin is used to maintain glycemic control in critically ill patients, often via intravenous infusion protocols.
• Hyperkalemia: The administration of insulin (with glucose to prevent hypoglycemia) facilitates intracellular shift of potassium, serving as an emergency treatment for severe hyperkalemia.

Therapeutic Uses of Glucagon

• Severe Hypoglycemia: This is the primary indication. Glucagon is administered when a patient with diabetes is unable to safely ingest oral carbohydrates due to unconsciousness or severe neuroglycopenia. It mobilizes hepatic glycogen stores to raise blood glucose.
• Diagnostic Aid: Used in radiology to temporarily inhibit gastrointestinal motility. It is also employed in provocative testing for certain endocrine disorders (e.g., assessing growth hormone or pheochromocytoma).
• β-Blocker or Calcium Channel Blocker Overdose: Glucagon’s positive inotropic and chronotropic effects, mediated independently of β-adrenergic receptors, can be beneficial in overdoses of these cardiac drugs.
• Inborn Errors of Metabolism: Used in acute management of certain disorders like glycogen storage disease type I to prevent hypoglycemia.

Adverse Effects

Insulin Adverse Effects

The most common and serious adverse effect of insulin therapy is hypoglycemia.

Hypoglycemia

Defined as a plasma glucose level <70 mg/dL (<3.9 mmol/L). Symptoms are categorized as autonomic (tremor, palpitations, sweating, hunger) and neuroglycopenic (confusion, drowsiness, speech difficulty, seizures, coma). Risk factors include excessive insulin dose, delayed or missed meals, increased physical activity, renal impairment, and alcohol consumption. Severe hypoglycemia requiring external assistance is a medical emergency.

Weight Gain

Insulin’s anabolic effects often lead to weight gain, which can exacerbate insulin resistance in type 2 diabetes. This necessitates concomitant lifestyle counseling.

Local Injection Site Reactions

• Lipohypertrophy: Swelling of fatty tissue due to repeated injection into the same site. It can lead to erratic insulin absorption.
• Lipoatrophy: Loss of subcutaneous fat; now rare with the use of human and analog insulins.
• Pain, redness, or itching: Usually mild and transient.

Allergic Reactions

Systemic allergic reactions are rare with modern recombinant human insulins. Localized IgE-mediated reactions may occur. Insulin antibodies, which rarely affect efficacy, can develop.

Hypokalemia

Insulin promotes cellular uptake of potassium. This effect is utilized therapeutically in hyperkalemia but can cause hypokalemia, particularly during treatment of hyperglycemic emergencies with high-dose insulin.

Peripheral Edema

Initiation or intensification of insulin therapy, especially in patients with previously poor glycemic control, can cause sodium retention and mild peripheral edema, which typically resolves.

Glucagon Adverse Effects

• Nausea and Vomiting: These are very common, occurring in up to 50% of patients, likely due to glucagon’s relaxant effect on gastrointestinal smooth muscle and direct central effects.
• Hyperglycemia: The intended therapeutic effect in hypoglycemia can become excessive if not monitored, especially in patients with residual endogenous insulin secretion.
• Hypotension: Transient decreases in blood pressure have been reported, though glucagon can also have positive cardiac effects.
• Tachycardia and Palpitations: Due to its positive chronotropic effects.
• Allergic Reactions: Rare but possible, including rash and anaphylaxis, particularly with older animal-sourced formulations. Recombinant glucagon carries lower risk.
• Headache and Dizziness: Less common effects.

Glucagon is contraindicated in patients with pheochromocytoma, as it may stimulate catecholamine release, and in insulinoma, where it may provoke profound hypoglycemia.

Drug Interactions

Insulin Drug Interactions

Many drugs can influence glycemic control and thus interact with insulin therapy.

• Drugs that Potentiate Insulin Effect (Increase Hypoglycemia Risk):
  • Oral Antidiabetic Agents: Concomitant use, particularly with sulfonylureas or meglitinides, increases hypoglycemia risk.
  • β-Adrenergic Blockers: Non-selective beta-blockers (e.g., propranolol) can mask the autonomic warning symptoms of hypoglycemia (tachycardia, tremor) and may impair counter-regulatory responses.
  • Alcohol: Inhibits gluconeogenesis, potentiating insulin-induced hypoglycemia, especially in a fasting state.
  • Angiotensin-Converting Enzyme (ACE) Inhibitors: May improve insulin sensitivity and increase hypoglycemia risk.
  • Salicylates (high dose), Pentamidine, Disopyramide: Can have hypoglycemic effects.
• Drugs that Antagonize Insulin Effect (Cause Hyperglycemia):
  • Glucocorticoids: Induce insulin resistance and stimulate gluconeogenesis.
  • Thiazide and Loop Diuretics: May cause hyperglycemia via hypokalemia-induced impairment of insulin secretion.
  • Sympathomimetics: Epinephrine, albuterol, and others stimulate glycogenolysis and gluconeogenesis.
  • Atypical Antipsychotics (e.g., olanzapine, clozapine): Promote weight gain and insulin resistance.
  • Protease Inhibitors, Atypical Antipsychotics, Phenytoin, Niacin: Can induce hyperglycemia.
• Other Interactions: Drugs affecting subcutaneous blood flow (e.g., vasodilators, vasoconstrictors) may alter insulin absorption.

Glucagon Drug Interactions

• β-Adrenergic Blockers: The cardiac effects of glucagon may be blunted in patients on non-selective beta-blockers, potentially reducing its efficacy in treating hypoglycemia in these individuals. Furthermore, beta-blockers can mask the tachycardia caused by glucagon.
• Anticholinergics: May potentiate glucagon’s gastrointestinal relaxant effects.
• Warfarin: Glucagon has been reported to potentiate the anticoagulant effect of warfarin, possibly by increasing its affinity for receptor sites. Monitoring of INR is advised with concomitant use.
• Indomethacin: May blunt the hyperglycemic response to glucagon.

Special Considerations

Pregnancy and Lactation

Insulin: Insulin is the drug of choice for glycemic control in pregnant individuals with pre-existing or gestational diabetes. It does not cross the placenta in significant amounts. Requirements often decrease in the first trimester, increase significantly in the second and third trimesters, and drop precipitously after delivery. Close monitoring and dose adjustment are mandatory. Insulin is considered compatible with breastfeeding.

Glucagon: Data on use in pregnancy is limited. It should be used only if clearly needed for severe hypoglycemia. It is not known if glucagon is excreted in human milk; caution is advised if administered to a nursing woman.

Pediatric Considerations

Insulin: Dosing is highly individualized and based on weight, age, pubertal status, and carbohydrate intake. Children are particularly susceptible to hypoglycemia, and regimens must be carefully balanced with variable activity levels and food intake. Insulin pumps are commonly used in pediatric populations. Rapid-acting and long-acting analogs are frequently preferred for their pharmacokinetic profiles.

Glucagon: Dosing for severe hypoglycemia is weight-based (20-30 μg/kg or 0.5-1 mg total dose). Caregivers must be trained in its reconstitution and administration. The availability of intranasal glucagon and auto-injectors has simplified emergency use.

Geriatric Considerations

Insulin: Older adults are at increased risk for hypoglycemia due to potentially impaired renal function, irregular meal patterns, polypharmacy, and blunted counter-regulatory responses. Simpler regimens (e.g., once-daily basal insulin) may be preferred to minimize risk. Glycemic targets may be relaxed to avoid hypoglycemia. Visual or dexterity impairments may necessitate assistive devices for insulin administration.

Glucagon: Standard doses are used. Caregivers in institutional settings should be trained in its use.

Renal Impairment

Insulin: The kidney is a major site of insulin clearance. In renal impairment (chronic kidney disease stages 4-5), insulin requirements often decrease by 25-50% due to reduced degradation and decreased renal gluconeogenesis. There is also an increased risk of prolonged hypoglycemia. Careful dose reduction and frequent glucose monitoring are essential.

Glucagon: Dosage adjustment in renal impairment is not typically required, though caution is advised due to limited data.

Hepatic Impairment

Insulin: The liver is the primary site of insulin metabolism. In severe hepatic impairment, insulin clearance may be reduced, potentially prolonging its effect and increasing hypoglycemia risk. Furthermore, impaired hepatic gluconeogenesis can also contribute to hypoglycemia. Insulin requirements may be variable; close monitoring is necessary.

Glucagon: Glucagon’s hyperglycemic action is entirely dependent on hepatic glycogen stores. In conditions of starvation, adrenal insufficiency, or chronic hypoglycemia where glycogen stores are depleted, glucagon will be ineffective. Its metabolism may also be impaired in liver disease, but this is not a primary dosing consideration.

Summary/Key Points

• Insulin and glucagon are pivotal counter-regulatory hormones governing glucose homeostasis. Insulin promotes anabolic storage processes, while glucagon stimulates catabolic mobilization of energy stores.
• Therapeutic insulin is classified by duration of action: rapid-acting, short-acting, intermediate-acting, and long-acting analogs, each with distinct pharmacokinetic profiles tailored for basal or prandial glycemic control.
• Insulin acts via a tyrosine kinase receptor, activating the PI3K/Akt pathway to stimulate glucose uptake (via GLUT4 translocation), glycogenesis, and lipogenesis, while inhibiting gluconeogenesis and lipolysis.
• Glucagon acts via a G_s-coupled GPCR, increasing intracellular cAMP and activating PKA to stimulate hepatic glycogenolysis and gluconeogenesis.
• The primary clinical use of insulin is the treatment of diabetes mellitus (types 1 and 2). Glucagon’s main use is the emergency treatment of severe hypoglycemia.
• Hypoglycemia is the most serious and common adverse effect of insulin therapy. Glucagon commonly causes nausea and vomiting.
• Numerous drugs interact with insulin by either potentiating (e.g., beta-blockers, alcohol) or antagonizing (e.g., glucocorticoids, thiazides) its glucose-lowering effect.
• Special vigilance is required in populations such as the elderly and those with renal impairment due to an elevated risk of hypoglycemia. Insulin is safe and preferred in pregnancy.

Clinical Pearls

• “Stacking” insulin doses—administering additional rapid-acting insulin too frequently before the previous dose has fully dissipated—is a common cause of unexpected hypoglycemia.
• In a patient with unexplained hypoglycemia on a stable insulin regimen, always consider and inspect for lipohypertrophy at injection sites, which can cause erratic absorption.
• Glucagon is ineffective in states of depleted hepatic glycogen stores (e.g., starvation, alcohol-induced hypoglycemia). Intravenous dextrose is the treatment of choice in these settings.
• When initiating or intensifying insulin therapy in type 2 diabetes, starting with a once-daily long-acting basal insulin is often the safest and simplest strategy, targeting fasting glucose first.
• Patient education on carbohydrate counting, sick-day management, and hypoglycemia recognition/treatment is as critical as the insulin prescription itself.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.